Work

Unraveling the Crimson puzzle: Two case reports/case series of hemorrhagic cystitis after combination chemotherapy with docetaxel, carboplatin, trastuzumab and pertuzumab in breast cancer

Year: 2025

Type: article

Abstract: RATIONALE: Hemorrhagic cystitis can be a serious side effect of some chemotherapy drugs like cyclophosphamide and ifosfamide. Docetaxel is a taxane that is used to treat several malignancies including breast and prostate cancer. Hemorrhagic cystitis has not been described as a complication of combination chemotherapy with docetaxel, particularly docetaxel with carboplatin, trastuzumab and pertuzumab (TCHP) in breast cancer patients. PATIENT CONCERNS: Both patients had a history of locally advanced human epidermal growth factor receptor 2 positive breast cancer and complaint of hematuria after their first treatment with TCHP. DIAGNOSES: They were diagnosed with hemorrhagic cystitis. INTERVENTIONS: Docetaxel was discontinued and changed to paclitaxel. OUTCOMES: Both patients completed neoadjuvant chemotherapy and did not have further episodes of hemorrhagic cystitis. LESSONS: Hemorrhagic cystitis is a rare complication of combination chemotherapy with docetaxel (TCHP). Clinicians should be vigilant for signs and symptoms of hemorrhagic cystitis in patients receiving docetaxel and alternative treatment option should be considered.

Source: Medicine

DOI: 10.1097/md.0000000000041906

Authors: Juan C. Ramirez, Mitchel E. Lacey, Maya S. Gowda, Grace Wang, Yolcar Chamorro, Ana C. Sandoval-Leon